(AUNA) Auna S.A. - Ratings and Ratios
Exchange: NYSE • Country: Luxembourg • Currency: USD • Type: Common Stock • ISIN: LU2791994721
AUNA: Healthcare, Hospitals, Clinics, Insurance, Plans
Auna S.A. (NYSE:AUNA) stands as a prominent healthcare service provider, operating an extensive network of hospitals and clinics across Mexico, Peru, and Colombia. Beyond traditional inpatient care, the company offers a diverse range of outpatient services, including specialized treatments and preventive healthcare programs. This comprehensive approach underscores their commitment to accessible and quality care across Latin America.
Founded in 1989 and headquartered in Luxembourg, Auna has carved a niche in the prepaid healthcare sector, particularly in Peru, where their plans are tailored to meet the unique demands of the local market. Additionally, in Mexico, they provide specialized dental and vision plans, enhancing their revenue streams and market reach. This strategic diversification has positioned Auna as a significant player in the regions healthcare industry.
From a technical standpoint, Aunas stock exhibits a short-term uptrend, with the 20-day SMA at 8.30 surpassing the 50-day SMA at 7.71. However, the 200-day SMA at 7.63 suggests a longer-term downtrend, signaling potential headwinds. The Average True Range (ATR) of 0.35 indicates low volatility, pointing to a stable yet uneventful trading environment in the near term.
Fundamentally, Aunas market capitalization of $638.65 million reflects its established presence, though the P/E ratio of 0.00 raises concerns about profitability. The price-to-book ratio of 1.59 and price-to-sales ratio of 0.15 suggest undervaluation, yet the negative return on equity of -8.10% highlights operational challenges. These factors collectively paint a picture of a company with growth potential tempered by financial constraints.
Looking ahead, the next three months may see Auna navigating a mixed trajectory. While the short-term technical strength could support modest gains, the broader market trends and company-specific challenges, including negative earnings, may limit upside potential. Investors should monitor operational efficiency improvements and any strategic initiatives aimed at addressing profitability concerns.
Additional Sources for AUNA Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
AUNA Stock Overview
Market Cap in USD | 499m |
Sector | Healthcare |
Industry | Medical Care Facilities |
GiC Sub-Industry | Health Care Facilities |
IPO / Inception | 2024-03-22 |
AUNA Stock Ratings
Growth 5y | -31.5% |
Fundamental | 61.9% |
Dividend | 0.0% |
Rel. Strength | -11.6 |
Analysts | 4.5/5 |
Fair Price Momentum | 6.14 USD |
Fair Price DCF | 294.94 USD |
AUNA Dividends
No Dividends PaidAUNA Growth Ratios
Growth Correlation 3m | -44.9% |
Growth Correlation 12m | -20.5% |
Growth Correlation 5y | -29.2% |
CAGR 5y | -28.53% |
CAGR/Max DD 5y | -0.70 |
Sharpe Ratio 12m | -0.99 |
Alpha | -11.02 |
Beta | 1.493 |
Volatility | 48.19% |
Current Volume | 5.6k |
Average Volume 20d | 15.7k |
As of April 08, 2025, the stock is trading at USD 6.77 with a total of 5,647 shares traded.
Over the past week, the price has changed by -4.78%, over one month by -17.44%, over three months by -1.88% and over the past year by -15.38%.
Yes, based on ValueRay Fundamental Analyses, Auna S.A. (NYSE:AUNA) is currently (April 2025) a good stock to buy. It has a ValueRay Fundamental Rating of 61.88 and therefor a positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of AUNA as of April 2025 is 6.14. This means that AUNA is currently overvalued and has a potential downside of -9.31%.
Auna S.A. has received a consensus analysts rating of 4.50. Therefor, it is recommend to buy AUNA.
- Strong Buy: 3
- Buy: 3
- Hold: 0
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, AUNA Auna S.A. will be worth about 6.6 in April 2026. The stock is currently trading at 6.77. This means that the stock has a potential downside of -2.07%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 13.4 | 97.2% |
Analysts Target Price | 14.7 | 116.7% |
ValueRay Target Price | 6.6 | -2.1% |